Bernstein Ups Coloplast Price Target, Tweaks EPS Forecasts After Fiscal Q3 Results

08:47 AM EDT, 08/19/2026 (MT Newswires) -- Bernstein raised its price target and tweaked its EPS estimates for Coloplast (COLO-B.CO) amid a model update following the Danish medical devices and services company's fiscal third-quarter results. Coloplast saw a 6% year-over-year organic growth in sales for the quarter, slightly above the 5.6% consensus estimate, while adjusted EBIT came in 1% below market forecasts, according to a Wednesday note. "Coloplast left FY25/26 guidance unchanged, continuing to expect +5-6% organic growth, around +5% EBIT growth in constant currencies and ROIC of around 15%. Management reiterated confidence in continued momentum across Chronic Care ex-China and high single-digit growth in Interventional Urology, which is currently tracking ahead of the assumptions embedded in Impact4," the research firm said. "However, uncertainty around mid-term guidance remains ongoing, with the new CEO Gavin Wood planning to provide a broader update at the Q4 FY25/26 results." With these in mind, the price target was changed to 455 Danish kroner from 450 kroner, while adjusted EPS forecasts for fiscal years 2026 and 2027 were revised to 25.47 kroner and 26.91 kroner, respectively, from 24.88 kroner and 26.99 kroner. The market-perform rating on the stock was retained.